These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26578)

  • 1. 2,5-Dimethoxy-4-methylamphetamine (DOM)- a central component of its cardiovascular effects in rats; involvement of serotonin.
    Friedman E; Lambert GA; Buchweitz E
    Eur J Pharmacol; 1978 May; 49(2):157-61. PubMed ID: 26578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
    Sanders-Bush E; Burris KD; Knoth K
    J Pharmacol Exp Ther; 1988 Sep; 246(3):924-8. PubMed ID: 2843634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular actions of 2,5-dimethoxy-4-methylamphetamine (DOM) in the cat.
    Tadepalli AS; Friedman E; Gershon S
    Eur J Pharmacol; 1975 Apr; 31(2):305-12. PubMed ID: 1056857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of d-lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-methylamphetamine (DOM) and d-amphetamine on operant responding in control and 6-hydroxydopamine-treated rats.
    Commissaris R; Lyness WH; Cordon JJ; Moore KE; Rech RH
    Pharmacol Biochem Behav; 1980 Nov; 13(5):621-6. PubMed ID: 7443731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naloxone alters the effects of LSD, DOM and quipazine on operant behavior of rats.
    Mokler DJ; Commissaris RL; Henck JW; Rech RH
    Pharmacol Biochem Behav; 1984 Sep; 21(3):333-7. PubMed ID: 6593750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex.
    Muschamp JW; Regina MJ; Hull EM; Winter JC; Rabin RA
    Brain Res; 2004 Oct; 1023(1):134-40. PubMed ID: 15364028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines.
    Glennon RA; Young R; Jacyno JM; Slusher M; Rosecrans JA
    Eur J Pharmacol; 1983 Jan; 86(3-4):453-9. PubMed ID: 6572591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) on schedule-controlled behavior.
    Harris RA; Snell D; Loh HH
    Pharmacol Biochem Behav; 1977 Oct; 7(4):307-10. PubMed ID: 928488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 2,5-dimethoxy-4-methylamphetamine on the behavior of rats in competition for food.
    Uyeno ET
    Int Pharmacopsychiatry; 1972; 7(1-4):244-8. PubMed ID: 4681210
    [No Abstract]   [Full Text] [Related]  

  • 10. MDA and DOM: substituted amphetamines that do not produce amphetamine-like discriminative stimuli in the rat.
    Shannon HE
    Psychopharmacology (Berl); 1980; 67(3):311-2. PubMed ID: 6770411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral characterization of 2-O-desmethyl and 5-O-desmethyl metabolites of the phenylethylamine hallucinogen DOM.
    Eckler JR; Chang-Fong J; Rabin RA; Smith C; Teitler M; Glennon RA; Winter JC
    Pharmacol Biochem Behav; 2003 Jul; 75(4):845-52. PubMed ID: 12957227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of d-lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-methylamphetamine (DOM), pentobarbital and methaqualone on punished responding in control and 5,7-dihydroxytryptamine-treated rats.
    Commissaris RL; Lyness WH; Rech RH
    Pharmacol Biochem Behav; 1981 May; 14(5):617-23. PubMed ID: 7243840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of 2,3-dihydrobenzofuran analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: drug discrimination studies in rats.
    Nichols DE; Hoffman AJ; Oberlender RA; Riggs RM
    J Med Chem; 1986 Feb; 29(2):302-4. PubMed ID: 3950910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible involvement of serotonin receptors in the facilitatory effect of a hallucinogenic phenethylamine on single facial motoneurons.
    Penington NJ; Reiffenstein RJ
    Can J Physiol Pharmacol; 1986 Oct; 64(10):1302-9. PubMed ID: 3801984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of 5-hydroxytryptamine in the central control of respiration, blood pressure and heart rate in the anaesthetized rat.
    Lambert GA; Friedman E; Buchweitz E; Gershon S
    Neuropharmacology; 1978 Oct; 17(10):807-13. PubMed ID: 34118
    [No Abstract]   [Full Text] [Related]  

  • 16. Serotonin excitation of facial motoneurons: receptor subtype characterization.
    Rasmussen K; Aghajanian GK
    Synapse; 1990; 5(4):324-32. PubMed ID: 2360199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discriminative stimulus properties of 2,5-dimethoxy-4-methylamphetamine (DOM): differentiation from amphetamine.
    Silverman PB; Ho BT
    Psychopharmacology (Berl); 1980; 68(3):209-15. PubMed ID: 6771804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.
    Pierce PA; Peroutka SJ
    J Pharmacol Exp Ther; 1988 Dec; 247(3):918-25. PubMed ID: 3204523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats.
    Fantegrossi WE; Harrington AW; Eckler JR; Arshad S; Rabin RA; Winter JC; Coop A; Rice KC; Woods JH
    Psychopharmacology (Berl); 2005 Sep; 181(3):496-503. PubMed ID: 15983786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the discriminative stimulus properties of centrally administered (-)-DOM and LSD.
    Doat MM; Rabin RA; Winter JC
    Pharmacol Biochem Behav; 2003 Feb; 74(3):713-21. PubMed ID: 12543238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.